GET TO KNOW OUR COMPANY
NEOTEC 2017 Programme – EXP-00104459/SNEO-20171251: Development of new drugs focused on psoriatic pruritus and neurocosmetics for the treatment of sensitive skin
RETOS-COLABORACIÓN 2017 Programme – RTC-2017-6507-1: Validation and pre-clinical development of new treatments for arthritic pain
Competitive Loan ENISA Crecimiento 2018 – Partial funding of the company’s strategic development plan
CREATEC-CV 2018 Programme – IMCBTA/2018/10: Development of a new neurocosmetical product for seborrheic dermatitis
CREATEC-CV 2019 Programme – IMCBTA/2019/19: Development of a new neurocosmetical product for chemical-induced sensitive skin
CDTI 2020 Programme – IDI-20200357: Preclinical development of new drugs for the treatment of psoriatic pruritus
This company is capitalized by Innvierte, a CDTI, E.P.E. investment programme
R&D Projects in Public-Private Collaboration – CPP2021-008824: Development of a new drug to treat psoriatic pruritus
Capital Cell investment round
Internationalization Strategic Consulting Program – ITCOES/2022/12: Internationalization of cosmetic ingredients
Support a la promoció exterior 2022 – INTPRM/2022/420
R&D Projects for SME (PIDI-CV) – IMIDTA/2023/83: Implementation of in silico processes for identification and development of cosmetic active ingredients that improve aging and/or diabetic-prone skin
Support a la promoció exterior 2023 – INTPRM/2023/918







